CHMP mener, at Menitorix under undersøgelsesbetingelserne giver tilstrækkelig immunrespons hos begge konjugatkomponenter til at yde en beskyttelse, som forventes at være mindst lige så god som de godkendte sammenlignende præparaters.
The CHMP considers that under the conditions of study, Menitorix elicits sufficient immune responses to both conjugate components to provide protection that is expected to be at least as good as that of licensed comparators.